Hepcinat LP is intended for the treatment of chronic hepatitis C genotype 1 in patients with and without cirrhosis. Effective for patients undergoing treatment for the first time and for patients with unsuccessful experience in treating hepatitis C with interferon and ribavirin or, if there is intolerance to these drugs. Ledipasvir and Sofosbuvir inhibit the two proteins necessary for the propagation of the hepatitis C virus. Sofosbuvir blocks an enzyme called "NS5B RNA-dependent RNA polymerase", while Ledipasvir inhibits a protein called "NS5A". By inhibiting these two proteins, Hepcinat LP Price prevents the hepatitis C virus from multiplying and infecting new cells.
Forum Topics Started
This user has not created any topics.